Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation-Reference-Cited by-同舟云学术

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation

Published:2017-12-02 Issue:3 Volume:61 Page:722-726
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

Uthman Laween,Baartscheer Antonius,Bleijlevens Boris,Schumacher Cees A.,Fiolet Jan W. T.,Koeman Anneke,Jancev Milena,Hollmann Markus W.,Weber Nina C.,Coronel Ruben,Zuurbier Coert J.

Funder

Academic Medical Center (AMC)

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/article/10.1007/s00125-017-4509-7/fulltext.html

Reference19 articles.

1. Reddy RPM, Inzucchi SE (2016) SGLT2 inhibitors in the management of type 2 diabetes. Endocrine 53:364–372

2. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128

3. Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657

4. Baartscheer A, Schumacher CA, Wüst RCI et al (2017) Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia 60:568–573

5. Yokoyama H, Gunasegaram S, Harding SE, Avkiran M (2000) Sarcolemmal Na+/H+ exchanger activity and expression in human ventricular myocardium. J Am Coll Cardiol 36:534–540

Cited by 460 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: Lessons from preclinical studies;Chemico-Biological Interactions;2024-11

2. Effectiveness of sodium-glucose co-transporter 2 inhibitors on atrial fibrillation recurrence after catheter ablation: A systemic review and meta-analysis;International Journal of Cardiology;2024-10

3. Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions;American Journal of Physiology-Cell Physiology;2024-09-01

4. 2024 ESC Guidelines for the management of chronic coronary syndromes;European Heart Journal;2024-08-30

5. SGLT2 inhibitor downregulated oxidative stress via activating AMPK pathway for cardiorenal (CR) protection in CR syndrome rodent fed with high protein diet;Journal of Molecular Histology;2024-08-27